Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen

Cancer Chemotherapy and Pharmacology

Volumn 46, Issue 6, 2000, Pages 507-516

  Taverna, Pietro ^a   Liu, Lili ^a   Hanson, Amy J ^a   Monks, Anne ^b   Gerson, Stanton L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

DNA mismatch repair; DNA repair; Drug resistance; NCI anticancer drug screen; Temozolomide

Indexed keywords

6 O ALKYLGUANINE DNA ALKYLTRANSFERASE; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CELL DNA; GENE PRODUCT; PLATINUM; PROTEIN MLH1; PROTEIN MSH2; TEMOZOLOMIDE; TRANSFERASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BASE MISPAIRING; CANCER; CELL LEVEL; CONTROLLED STUDY; DATA BASE; DNA REPAIR; DRUG SCREENING; DRUG SENSITIVITY; DRUG TARGETING; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEFECT; TUMOR CELL LINE; WESTERN BLOTTING;

EID: 0033647208     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800000186     Document Type: Article

References (41)

1. Mismatch repair in replication fidelity, genetic recombination, and cancer biology
2. Clues to the pathogenesis of familial colorectal cancer
3. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer
4. Microsatellite instability in inherited and sporadic neoplasms
5. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype
6. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability
7. Genetic instability of microsatellites in endometrial carcinoma
8. Genetic instability in pancreatic cancer and poorly differentiated type of gastric cancer
9. Isolation of an MSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells
10. hMutSbeta, a heterodimer of MSH2 and hMSH3, binds to insertion/deletion loops in DNA
11. Restoration of mismatch repair to nuclear extracts of H6 colorectal tumor cells by a heterodimer of human MutL homologs
12. The role of DNA mismatch repair in drug resistance
13. An information-intensive approach to the molecular pharmacology of cancer
14. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm
15. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea
16. Multidrug-resistant phenotype of disease-oriented panels of human tumor cell lines used for anticancer drug screening
17. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen
18. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen
19. Overlapping phenotypes of multidrug resistance among panels of human cancer-cell lines
20. Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes
21. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents
22. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines
23. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines
24. Mutations predisposing to hereditary nonpolyposis colorectal cancer: Database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer
25. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients
26. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: Implications for clinical predisposition testing
27. Microsatellite instability and mutation analysis of MSH2 and MLH1 in patients with sporadic, familial and hereditary colorectal cancer
28. MSH2 and MLH1 mutations in sporadic replication error-positive colorectal carcinoma as assessed by two-dimensional DNA electrophoresis
29. Altered expression of MSH2 and MLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes
30. Biallelic inactivation of MLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers
31. Hypermethylation of the MLH1 promoter in colon cancer with microsatellite instability
32. MLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis
33. Diagnostic microsatellite instability: Definition and correlation with mismatch repair protein expression
34. Immunohistochemistry for MLH1 and MSH2: A practical test for DNA mismatch repair-deficient tumors
35. Mutations and loss of expression of a mismatch repair gene, MLH1, in leukemia and lymphoma cell lines
36. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines
37. Genetic instability in human ovarian cancer cell lines
38. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N- nitrosoguanidine tolerance in colon tumor cells with homozygous MLH1 mutation
39. Microsatellite instability is associated with genetic alteration but not with low levels of expression of the human mismatch repair proteins hMSH2 and hMLH1
40. Loss of DNA mismatch repair: Effects on the rate of mutation to drug resistance
41. Comparison of O6-alkylguanine-DNA alkyltransferase activity based on cellular DNA content in human, rat and mouse tissues